Form 8-K - Current report:
SEC Accession No. 0001193125-22-022449
Filing Date
2022-01-31
Accepted
2022-01-31 08:30:57
Documents
12
Period of Report
2022-01-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d292852d8k.htm   iXBRL 8-K 22668
  Complete submission text file 0001193125-22-022449.txt   147666

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cadl-20220128.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20220128_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20220128_pre.xml EX-101.PRE 11710
6 EXTRACTED XBRL INSTANCE DOCUMENT d292852d8k_htm.xml XML 3548
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 22571448
SIC: 2836 Biological Products, (No Diagnostic Substances)